OSU-2S 是一种有效的PKCδ激活剂。OSU-2S 抑制细胞增殖和迁移。当与 Sorafenib (HY-10201) 连用时，降低 p-ERK1/2 的表达，增加 PKCδ (38 kDa) 的表达。OSU-2S 诱导细胞凋亡 (Apoptosis)。OSU-2S slao 是 FTY720 的非免疫抑制类似物。OSU-2S 具有抗癌活性。
| 生物活性 | OSU-2S is a potentPKCδactivator. OSU-2S inhibits cell proliferation and migration. OSU-2S decreases the expression of p-ERK1/2, increases the expression ofPKCδ(38 kDa) when combined withSorafenib(HY-10201). OSU-2S inducesApoptosis. OSU-2S slao is a non-immunosuppressive analogue of FTY720. OSU-2S shows anticancer activity[1][2]. |
| IC50& Target[1] | |
体外研究
(In Vitro) | OSU-2S (1.25, 2.5 μM; 48 h) 与Sorafenib(HY-10201) (2.5, 5 μM) 联用时，降低 p-ERK1/2 的表达，增加 PKCδ (38 kDa) 的表达[1]。
OSU-2S/Sorafenib (1.25, 2.5 μM; 8 h) 组合抑制细胞增殖和迁移[1]。
OSU-2S (0, 1, 2.5, 5 μM; 0-24 h) 以剂量和时间依赖性方式降低 Hep3B 细胞中 PARP 的表达[2]。
OSU-2S (5 μM; 12, 24 h) 诱导 Hep3B 细胞凋亡[2]。
OSU-2S (0-10 μM; 1 h) 以剂量依赖性方式刺激 Hep3B、Huh7、PLC-5 细胞中 ROS 的产生[2]。
Cell Proliferation Assay[1] | Cell Line: | Hep3B, Huh7, PLC-5, HepG2 cells | | Concentration: | 0-10 μM | | Incubation Time: | 48 h | | Result: | Showed anti-proliferative effects with IC50s of 2.53, 2.41, 3.96, 1.84 μM for Hep3B, Huh7, PLC-5, HepG2 cells, respectively. |
Western Blot Analysis[1] | Cell Line: | Hep3B cells | | Concentration: | 1.25, 2.5 μM combinated with sorafenib (2.5, 5 μM) | | Incubation Time: | 48 h | | Result: | Decreased the expression of ERK1/2 phosphorylation, increased the expression of PKCδ (38 kDa) when sorafenib/OSU-2S combination. |
|
体内研究
(In Vivo) | OSU-2S (5, 10 mg/kg; i.p.; once daily for 42 days) 抑制小鼠的肿瘤生长[2]。
| Animal Model: | CD2F1 mice (Hep3B tumor xenograft models)[2] | | Dosage: | 5, 10 mg/kg | | Administration: | I.p.; once daily for 42 days | | Result: | Exhibited a higher tumor-suppressive potency, achieving 80% reduction in bioluminescence at the end of treatment. |
|
| 分子量 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com